Advanced Life Sciences Holdings Inc. is proceeding with its new drug application (NDA) for cethromycin in community-acquired pneumonia (CAP) after results of the second of two pivotal clinical trials showed that the ketolide antibiotic met its primary endpoint of statistical noninferiority cure rates. (BioWorld Today)